Asthma Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | AstraZeneca, KeyMed Biosciences, Sterna Biologics, Landos Biopharma, Lanier

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Asthma pipeline constitutes 80+ key companies continuously working towards developing 90+ Asthma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Asthma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Asthma Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Asthma Market.

Some of the key takeaways from the Asthma Pipeline Report:

Companies across the globe are diligently working toward developing novel Asthma treatment therapies with a considerable amount of success over the years.

Asthma companies working in the treatment market are Landos Biopharma, Lanier Biotherapeutics, Kinaset therapeutics, AstraZeneca, KeyMed Biosciences, Sterna Biologics, Chia Tai Tianqing Pharmaceutical Group, GlaxoSmithKline, Areteia Therapeutics, and others, are developing therapies for the Asthma treatment

Emerging Asthma therapies in the different phases of clinical trials are- LABP-73, LNR 125.38, KN-002, AZD8630, CM326, SB010, TQC2731, GSK3511294, Dexpramipexole, and others are expected to have a significant impact on the Asthma market in the coming years.

In March 2024 Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, announced the dosing of the first patients in its Phase 2 VALIANT clinical trial of verekitug (UPB-101) in patients with severe asthma.

In February 2024, Areteia Therapeutics announced the $75 million in additional Series A financing to support expansion of the current Phase III development program of dexpramipexole in eosinophilic asthma, bringing total Series A funding to $425 million. Viking Global Investors and Marshall Wace join the original syndicate of investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners

In October 2023, Aiolos Bio announced that it raised $245 million in Series A funding. Atlas Venture, Bain Capital Life Sciences, Forbion Capital Partners and Sofinnova Investments led the round, with additional investment from RA Capital Management. Aiolos plans to use the funds for phase 2 clinical trials of its lead drug candidate, AIO-001, for moderate-to-severe asthma patients.

In January 2023, Areteia Therapeutics initiated a randomized, double-blind, placebocontrolled, parallel-group study to assess the efficacy, safety, and tolerability of Dexpramipexole administered orally for 24 weeks in participants with Eosinophilic Asthma. The trial is currently recruiting the participants and is anticipated to be completed in March 2025 with an enrollment of 550 participants.

Asthma Overview

Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, which can lead to symptoms such as wheezing, coughing, chest tightness, and shortness of breath.

Get a Free Sample PDF Report to know more about Asthma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/asthma-pipeline-insight

 

Emerging Asthma Drugs Under Different Phases of Clinical Development Include:

LABP-73: Landos Biopharma

LNR 125.38: Lanier Biotherapeutics

KN-002: Kinaset therapeutics

AZD8630: AstraZeneca

CM326: KeyMed Biosciences

SB010: Sterna Biologics

TQC2731: Chia Tai Tianqing Pharmaceutical Group

GSK3511294: GlaxoSmithKline

Dexpramipexole: Areteia Therapeutics

 

Asthma Route of Administration

Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Asthma Molecule Type

Asthma Products have been categorized under various Molecule types, such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Asthma Pipeline Therapeutics Assessment

Asthma Assessment by Product Type

Asthma By Stage and Product Type

Asthma Assessment by Route of Administration

Asthma By Stage and Route of Administration

Asthma Assessment by Molecule Type

Asthma by Stage and Molecule Type

DelveInsight’s Asthma Report covers around 90+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I)

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Further Asthma product details are provided in the report. Download the Asthma pipeline report to learn more about the emerging Asthma therapies

 

Some of the key companies in the Asthma Therapeutics Market include:

Key companies developing therapies for Asthma are – AstraZeneca PLC, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Novartis AG, F. Hoffmann-La Roche Ltd, Pfizer Inc., Grifols SA, Merck & Co. Inc., Sanofi SA, Sumitomo Dainippon Pharma Co. Ltd, Teva Pharmaceutical Industries Ltd, Chiesi Farmaceutici SpA, and others.

Asthma Pipeline Analysis:

The Asthma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Asthma with aggregate therapies developed by each company for the same.

It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Asthma Treatment.

Asthma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

Asthma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Asthma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Asthma drugs and therapies

 

Asthma Pipeline Market Drivers

The rising global prevalence of asthma presents a substantial market driver as it fuels demand for asthma management products, including medications, inhalers, and respiratory devices.

Asthma Pipeline Market Barriers

The high cost of asthma medications serves as a barrier by limiting accessibility for patients, particularly in regions with lower socioeconomic status or inadequate healthcare coverage. This barrier hampers treatment adherence, exacerbates health disparities.

 

Scope of Asthma Pipeline Drug Insight    

Coverage: Global

Key Asthma Companies: Landos Biopharma, Lanier Biotherapeutics, Kinaset therapeutics, AstraZeneca, KeyMed Biosciences, Sterna Biologics, Chia Tai Tianqing Pharmaceutical Group, GlaxoSmithKline, Areteia Therapeutics, and others

Key Asthma Therapies: LABP-73, LNR 125.38, KN-002, AZD8630, CM326, SB010, TQC2731, GSK3511294, Dexpramipexole, and others

Asthma Therapeutic Assessment: Asthma current marketed and Asthma emerging therapies

Asthma Market Dynamics: Asthma market drivers and Asthma market barriers 

 

Request for Sample PDF Report for Asthma Pipeline Assessment and clinical trials

 

Table of Contents

1. Asthma Report Introduction

2. Asthma Executive Summary

3. Asthma Overview

4. Asthma- Analytical Perspective In-depth Commercial Assessment

5. Asthma Pipeline Therapeutics

6. Asthma Late Stage Products (Phase II/III)

7. Asthma Mid Stage Products (Phase II)

8. Asthma Early Stage Products (Phase I)

9. Asthma Preclinical Stage Products

10. Asthma Therapeutics Assessment

11. Asthma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Asthma Key Companies

14. Asthma Key Products

15. Asthma Unmet Needs

16 . Asthma Market Drivers and Barriers

17. Asthma Future Perspectives and Conclusion

18. Asthma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Stay up to date
Register now to get updates on promotions and coupons

Shopping cart

×